Farzanegan Pub Farzanegan DOI info@joas.ir mEDRA 20260527 DOI Registration 01

06 10.22034/zagros.2021.0227.0745 https://ieaj.ir/user/articles/1405 Farzanegan Pub mEDRA 01 01 1405 zagros Publisher IR 01 1405 JB 48 1 4 01 202605 7 10 01 1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2017 ;144: 646.47. 2. Kanellopoulou C, Monticelli S . A role for microRNAs in the development of the immune system and in the pathogenesis of cancer. Semin Cancer Biol. 2018 ; 18:79-88. 3. Kim M, Kasinski AL, Slack FJ. MicroRNA therapeutics in preclinical cancer models. Lancet Oncol. 2017; 12: 319-12. 4. Lim , Li J , Ding X , He M , Chang SY . microRNA and cancer . AAPS J. 2016 ;12:309-71. 5. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000; 100:57-07. 6. Sonnenschein C, Soto AM. Theories of carcinogenesis: an emerging perspective. Semi Cancer Biol. 2018; 18: 372-7. 7. Ranjbar M.M1, Mousavi Nasab S.D, Ahmadi N, Basati G. Promising therapeutic approaches for cancer based on unique features of apoptin protein from chicken anemia virus. Scientific J of Ilam Uni Med Sci. 2012; 20:157-861. 8. Workman P. Genomics and the second golden era of cancer drug development. Mol BioSyst 2015; 1:17-26. 9. Kourou K, I. Fotiadis D. Computational modelling in cancer: methods and applications. Biomedical data journal. 2015; 1:15-25. 10. Workman P. Drugging the cancer kinome: progress and challenges in developing personalised molecular cancer therapeutics. Cold Spring Harb Symp Quant Biol 2015; 70: 499-515. 11. National Cancer Institute - Cancer Trends Progress Report -2009/2010. 12. Wadood A, Ahmed N, Shah L, Ahmad A, Hassan H, Shams S. In-silico drug design: an approach which revolutionarised the drug discovery process. OA Drug Design & Delivery, 2013; 1(1): 3. 13. Kinnings SL, Liu N, Buchmeier N, Tonge PJ, Xie L. Drug discovery using chemical systems biology: repositioning the safe medicine comtan to treat multi-drug and extensively drug resistant tuberculosis. PLoS Comput Biol, 2019; 5(7). 14. Campillos M, Kuhn M, Gavin AC, Jensen LJ, Bork P Drug target identification using side-effect similarity. Science. 2018.321: 263-266. 15. Begg AC, Stewart FA, Vens C. Strategies to improve radiotherapy with targeted drugs. Nat Rev Cancer. 2016; 11: 239-53. 16. Poulikakaos PI, Rosen N. Mutant BRAF melanomas-dependence and resistance. Cancer Cell. 2014; 19: 5-11. 17. Clemons PA. Complex phenotypic assays in high-throughput screening. Curr Opin Chem Biol 2014; 8: 334–8. 18. Macarron R, Banks MN, Bojanic D, Burns DJ, Cirovic DA, Garyantes T, et al. Impact of high-throughput screening in biomedical research. Nat Rev Drug Discov 2016; 10: 188–95. 19. Van Montfort RL, Workman P. Structure-based design of molecular cancer therapeutics. Trends Biotechnol, 2019; 27: 315-28. 20. Halling-Brown MD, Bulusu KC, Patel M, Tym JE, Al-Lazikani B. canSAR: an integrated cancer public translational research and drug discovery resource. Nucleic Acids Res 2016; 40: 947-65. 21. Bolgar B, Arany A, Temesi G. et al., Drug repositioning for treatment of movement disorders: from serendipity to rational discovery strategies. Curr Top Med Chem 2018; 81,2337-36. 22. Hileman B. Accounting for R&D, Many doubt the $800 million pharmaceutical price tag. Chemical. Eng. News. 2016, 84:50. 15. 23. Li J, Zheng S, Chen B, J. Butte A, Swamidass S, Lu Zh. A survey of current trends in computational drug repositioning. Brief Bioinform, 2015; 17: 2-12. 24. Chandran d, k. Pappachen l, prathap m, m.j j, jilsha g. Insilico drug design and molecular docking studies of some novel benzothiazole derivatives as anti-cancer and antiinflammatory agents. Int J of pharmacy and pharmaceutical sciences, 2014; 6: 203-208. 25. El-zahar1 M, s. Abd el-karim1S, Haiba1 M, Khedr M. Synthesis, antitumor activity and molecular docking study Of novel benzofuran-2-yl pyrazole pyrimidine derivatives. Acta Poloniae Pharmaceutica Drug Research, 2017; 68 (3): 357-373. 26. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature 2017; 417: 949-54. 27. Riahi S, Eynollahi S, Ganjali MR.Computational studies on effects of MDMA as an anticancer drug on DNA. Chem Biol Drug Des, 2019; 76(5): 425-32. 28. KPS A, Babu P A, Kumar Palakeerthi S. In Silico lead identification by virtual screening and in vitroanti-cancer activities by MTT assay. Int Journal of Computational Bioinformatics and In Silico Modeling, 2017; 1(5): 55-75. 29.J. A. Greathouse and V. C. A. Hanratty, Spreadsheet Applications in Chemistry Using Microsoft Excel (Diamond, Dermot; Hanratty, Venita C. A), John Wiley & Sons, 2018. 30.E. Morgan, Chemometrics: Experimental Design (Analytical Chemistry by Open Learning), John Wiley & Sons Inc, 2017. 31. Wu W, Zhang R, R. Salahub D. Nelfinavir: A magic bullet to annihilate cancer cells. Cancer Biology & Therapy, 2019; 8(3): 233-532. 32. Chandran d, k. Pappachen l, prathap m, jinsha m.j, jilsha.g. in silico drug design and molecular docking study of thalidomide derivatives as tubulin-polymerization inhibitors. Int J of Pharmacy and Pharmaceutical Sciences, 2014; 6. 1 A01 سیده طاهره سادات احمدی سیده طاهره سادات احمدی C. سیده طاهره سادات احمدی 01 eng 202605 2026 C. zagros